HER2 Support Group Forums - View Single Post - 7 years & counting...NED still elusive. Chest nodes back.

Rich66 · 04-23-2009, 06:54 PM

In case you are ER+

1: Gan To Kagaku Ryoho. 2009 Apr;36(4):671-3.

[A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene.]

[Article in Japanese]

Murata T, Yoshino H, Bandou H, Morita K, Kurokawa M, Inaki N, Kotake M, Kadoya S, Yamamoto M, Takayanagi T, Yamada T.
Dept. of General and Gastroenterological Surgery, Ishikawa Prefectural Central Hospital.
The patient was a 56-year-old female. At the age of 35 years, she had under gone left mastectomy and axillary lymph node dissection for breast cancer. After surgery, hormonal therapy was continued for 3 years. Then, no treatment was performed. In this study, single therapy with an AI agent was started to treatbilateral supraclavicular fossa/mediastinal lymphnode metastases. After 6 months, a partial response(PR)was achieved. However, progression of the disease(PD)was noted after 1 year. Thereafter,the regimen was switched to single high-dose(120mg/day)TOR therapy. CT revealed the disappearance of the bilateral supraclavicular fossa lymphnodes and a marked reduction of the other lymphnodes. Currently, the patient is being treated, with an interval of 10 months from the start of TOR therapy.

04-23-2009, 06:54 PM	#7
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	In case you are ER+ 1: Gan To Kagaku Ryoho. 2009 Apr;36(4):671-3. [A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene.] [Article in Japanese] Murata T, Yoshino H, Bandou H, Morita K, Kurokawa M, Inaki N, Kotake M, Kadoya S, Yamamoto M, Takayanagi T, Yamada T. Dept. of General and Gastroenterological Surgery, Ishikawa Prefectural Central Hospital. The patient was a 56-year-old female. At the age of 35 years, she had under gone left mastectomy and axillary lymph node dissection for breast cancer. After surgery, hormonal therapy was continued for 3 years. Then, no treatment was performed. In this study, single therapy with an AI agent was started to treatbilateral supraclavicular fossa/mediastinal lymphnode metastases. After 6 months, a partial response(PR)was achieved. However, progression of the disease(PD)was noted after 1 year. Thereafter,the regimen was switched to single high-dose(120mg/day)TOR therapy. CT revealed the disappearance of the bilateral supraclavicular fossa lymphnodes and a marked reduction of the other lymphnodes. Currently, the patient is being treated, with an interval of 10 months from the start of TOR therapy.